Drugs utilized to treat systemic diseases can do harm to the eye and its neural connections.
With the increasing use of injected semaglutide (Ozempic, Wegovy; Novo Nordisk) for the treatment of type 2 diabetes and obesity, it is not surprising that patients taking a semaglutide when examined by an eye care professional also have one or more ocular diseases. The challenge is differentiating causation from correlation. Causation means that one event, such as being treated with a semaglutide, results in another, such as vision-threatening nonarteritic anterior ischemic optic neuropathy (NAION).